DrugDashboards

lecanemab

lecanemab · LECANEMAB 360 mg/1.8mL · Injection, Solution · Terumo Corporation

NDC 53877-0901-01 · 128 SYRINGE in 1 BOX / 1.8 mL in 1 SYRINGE · DRUG FOR FURTHER PROCESSING · View full market →

Bulk ingredient — not a finished product

This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.

Medicare Part D

This is a bulk ingredient, not a dispensable product — it is a raw material sold to manufacturers and compounders, so no plan prices it.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
TE code
Approval date
Patents / exclusivity

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of lecanemab (Injection, Solution)

LabelerStrengthFirst seenLast seen
Eisai Inc.LECANEMAB 100 mg/mLJul 15, 2026Sep 3, 2026
Terumo CorporationLECANEMAB 250 mg/1.25mLJul 15, 2026Sep 2, 2026
Terumo CorporationLECANEMAB 360 mg/1.8mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "lecanemab — NDC 53877-0901-01," retrieved September 3, 2026, https://drugdashboards.com/drug/53877090101.

Free to cite with attribution — see how the data is put together.